While future studies are needed to thoroughly assess the additional consequences of inhibition of CRBN, based on the current data, modulation of DNAJB1 by inhibiting CRBN represents a promising new therapeutic for PD. This evidence concerns the gene DNAJB1 and Parkinson disease.